Forbes A, Johnson P J, Williams R
J R Soc Med. 1985 Oct;78(10):826-9. doi: 10.1177/014107688507801007.
A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.
报告了一项重组人γ干扰素治疗无法切除的原发性肝细胞癌的II期试验。由于毒性不可接受（主要是肾脏毒性），该试验在仅招募7名患者后提前终止。7名患者中均无反应证据，但有一些证据表明在治疗期间疾病进展更快。
